Marko S. Zatylny

Partner

Zatylny-Marko-300
  • JD, Harvard Law School, 2002
  • BS (Accounting), magna cum laude, Brigham Young University, 1998

Qualifications

  • Massachusetts, 2002
  • Legal 500 (2016)
  • “Dealmaker of the Week” The American Lawyer (2015)
  • IFLR1000: The Guide to the World’s Leading Financial Law Firms, Rising Star (2014-2016)
  • “Dealmaker of the Week” The American Lawyer (2012)

Marko S. Zatylny

Partner

Marko focuses his practice on advising public and private companies, investment banks and investment funds in mergers & acquisitions, capital markets transactions and corporate governance issues. He handles transactions for clients in a number of industries, including life sciences, financial services, energy/infrastructure and retail and consumer. His clients include companies such as Becton Dickinson, Domino’s Pizza, IMS Health, LPL Financial, Pfizer and Wright Medical. Marko is co-chair of the firm’s energy/infrastructure group. In April 2012 and February 2015, Marko was named “Deal Maker of the Week” by The American Lawyer.

Experience

  • Pfizer in its acquisition of Hospira for approximately $17 billion.
  • Wright Medical in its merger of equals with Tornier NV.
  • Novavax in its cross-border tender offer for the outstanding shares of Isconova, a Sweden-based publicly traded vaccine adjuvant company.
  • Wright Medical in its sale of its OrthoRecon business to Hong Kong-based MicroPort Scientific Corporation.
  • Veolia and I Squared Capital in their acquisition of the Kendall Square Power Station, a 256 megawatt producer of electrical and steam energy.
  • Wright Medical in its sale of its $290 million OrthoRecon business to Hong Kong-based MicroPort Scientific Corporation. 
  • Becton Dickinson in its recent acquisitions of GenCell Biosystems and CRISI Medical Systems.
  • Pfizer in its acquisition of Excaliard Pharmaceuticals, a biopharmaceutical company focused on the development of novel drugs for the treatment of skin scarring.
  • The lead underwriters in the $214 million IPO for Multi Packaging Solutions International.
  • The lead underwriters in the $1 billion follow-on offering for HD Supply Holdings.
  • The lead underwriters in the initial public offering of Cerulean Pharma.
  • The lead underwriters in the follow-on offering of Insmed Incorporated.
  • The lead underwriters in the initial public offering and subsequent follow-on offerings of Bloomin’ Brands, one of the largest casual dining restaurant companies in the world.
  • LPL Financial, the nation's largest independent broker-dealer, in its $522 million initial public offering and subsequent follow on offerings.
  • Covidien in its $2.6 billion acquisition of ev3, Inc. 
  • Becton Dickinson in the $730 million sale of its Discovery Labware, a manufacturer and distributor of diagnostic and research tools division, to Corning, a producer of specialty glasses, ceramics, and related materials worldwide. 
  • URL Pharma, Inc. in its $800 million sale to Takeda Pharmaceuticals, a developer of diabetes, cardiovascular disease, and gastroenterology pharmaceuticals.
  • LPL Financial in its acquisition of Concord Wealth Management. 
  • Represented clients in acquisitions of energy/utility assets and the negotiation of various power and energy contracts, including in the renewable energy sector.

Publications

Presentations

  • Panelist, “From the Boardroom: Considerations in Option to Purchase Deals,” Ropes & Gray Life Sciences Roundtable, San Francisco, January 12, 2014